Northern Biologics, the relatively young organization that specializes in intelligent immune-oncology products, acquired some impressive new leadership this past month. “Dr. Vickers is a preeminent R&D leader with more than two decades of experience in the biotech and pharmaceutical industry” Philip Vickers was announced as the new CEO on November 9th. Vickers joins Northern Biologics from the Executive Committee for Shire where he was the head of Research & Development.
“We feel very fortunate to have attracted someone of Phil’s reputation and calibre as the new leader of Northern Biologics. He brings critical experience and a track record in drug development to take Northern Biologics into its next phase of growth”
- Brad Bolzon, Ph.D., chairman of Northern Biologics and Versant Ventures.
Fresh reputable talent is going to help boost Canadian company importance throughout the biotech and pharmaceutical industry. This type of acquisition will not only encourage steps forward in generating a strong Canadian industry reputation, but it will also inspire other Canadian companies to keep pace. Hopefully, we will see other national competitors start to invest in similar personnel hirings.
Read more here!
Join in on the conversation with Ella Korets-Smith when you subscribe to Toronto Health.